Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons
- PMID: 20702792
- PMCID: PMC2938971
- DOI: 10.1212/WNL.0b013e3181f11bd8
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons
Abstract
Objective: To determine factors associated with baseline neurocognitive performance in HIV-infected participants enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) neurology substudy.
Methods: Participants from Australia, North America, Brazil, and Thailand were administered a 5-test neurocognitive battery. Z scores and the neurocognitive performance outcome measure, the quantitative neurocognitive performance z score (QNPZ-5), were calculated using US norms. Neurocognitive impairment was defined as z scores <-2 in two or more cognitive domains. Associations of test scores, the QNPZ-5, and impairment with baseline factors including demographics and risk factors for HIV-associated dementia (HAD) and cardiovascular disease (CVD) were determined in multiple regression.
Results: The 292 participants had a median CD4 cell count of 536 cells/mm(3), 88% had an HIV viral load < or =400 copies/mL, and 92% were taking antiretrovirals. Demographics, HIV, and clinical factors differed between locations. The mean QNPZ-5 score was -0.72; 14% of participants had neurocognitive impairment. For most tests, scores and z scores differed significantly between locations, with and without adjustment for age, sex, education, and race. Prior CVD was associated with neurocognitive impairment. Prior CVD, hypercholesterolemia, and hypertension were associated with poorer neurocognitive performance but conventional HAD risk factors and the CNS penetration effectiveness rank of antiretroviral regimens were not.
Conclusions: In this HIV-positive population with high CD4 cell counts, neurocognitive impairment was associated with prior CVD. Lower neurocognitive performance was associated with prior CVD, hypertension, and hypercholesterolemia, but not conventional HAD risk factors. The contribution of CVD and cardiovascular risk factors to the neurocognition of HIV-positive populations warrants further investigation.
Figures
Comment in
-
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.Neurology. 2011 Jul 26;77(4):406-7; author reply 467. doi: 10.1212/WNL.0b013e3182246ffb. Neurology. 2011. PMID: 21788620 No abstract available.
References
-
- McArthur JC Hoover DR Bacellar H et al. Dementia in AIDS patients: incidence and risk factors: Multicenter AIDS Cohort Study. Neurology. 1993;43:2245–2252. - PubMed
-
- Bhaskaran K Mussini C Antinori A et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63:213–221. - PubMed
-
- El-Sadr WM Lundgren JD Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296. - PubMed
-
- Anstey KJ von Sanden C Salim A O'Kearney R Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367–378. - PubMed
-
- Hayden KM Zandi PP Lyketsos CG et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord. 2006;20:93–100. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials